Navigation Links
Spectros Signs New International Distribution Deals
Date:11/4/2009

PORTOLA VALLEY, Calif., Oct. 19 /PRNewswire/ -- Spectros, developer and manufacturer of advanced molecular sensing and imaging devices which shed light on life-threatening diseases, announced today that it has signed exclusive distribution deals for both its T-Stat® VLS Tissue Oximeter and Sensors. The markets covered include Australia, New Zealand, The Netherlands, Belgium, Luxembourg (Benelux), Suriname, Italy, France, Spain, Portugal, Poland, Greece, Turkey, and Russia. The values of the deals were not disclosed.

Founded in 1995, Spectros develops tissue oximeters and sensors for various uses with applications in critical care, gastroenterology, colon-rectal surgery, plastic surgery, and vascular surgery. T-Stat® VLS Tissue Oximeter is an FDA-approved and CE Marking device approved for neonatal, pediatric, and adult use.

"We are proud to be working with our new partners, Endovations in Australia, Fysicon Medical Technology in the Netherlands, and A.M.I. Italia s.r.l. in Italy, who are providing the T-Stat® franchise in their respective markets in order to realize our potential," said David Benaron, CEO of Spectros. "Support of our technology is a testament to their commitment to offering their healthcare communities with innovative and life-saving solutions," commented Robert Kum, director of commercial development.

The T-Stat® franchise includes the T-Stat® VLS Tissue Oximeter, utilizing Visible Light Spectroscopy (VLS), a multi-wavelength, noninvasive, continuous, real-time monitor of absolute hemoglobin oxygen saturation. The T-Stat® Sensors allow for ischemia monitoring in various applications, including critical care (neonatal, pediatric, and adult), gastroenterology (G.I. ischemia diagnosis), colon-rectal surgery (anastomosis), plastic surgery (free flaps), and vascular surgery (AAA, TAAA, and EVAR).

Based in Australia, Endovations Pty. Ltd. is a leader in the field of critical care, respiratory, anesthesia, and surgical applications. Endovations will distributor the T-Stat® VLS Tissue Oximeter and Sensors to the Australian and New Zealand markets.

Based in the Netherlands, Fysicon Medical Technology is a leader in the field of cardiology. The company will distribute the T-Stat® VLS Tissue Oximeter and Sensors to the Dutch, Belgium, and Luxembourgian (Benelux), and Suriname markets.

Based in Italy, A.M.I. Italia s.r.l. is a leader in the patient monitoring market. A.M.I. will distribute the T-Stat® VLS Tissue Oximeter and Sensors in Italy, France, Spain, Portugal, Poland, Greece, Turkey, and Russia.

About Spectros

Spectros markets advanced molecular sensing and imaging devices that shed light on ischemia and cancer. The company's lead product, the T-Stat Tissue Oximeter, was the first medical device FDA approved as sensitive to ischemia, an insufficient blood flow to tissue. T-Stat is the only commercially available tissue oximeter that utilizes state-of-the-art visible light spectroscopy (VLS) technology. In clinical use, T-Stat is a real-time, absolute, non-invasive, and continuous tissue monitor that analyzes 260 wavelengths of light, far more than the 2-4 wavelengths used in other monitors for superior accuracy. Spectros is also developing molecular diagnostic tools for breast and prostate cancer currently in phase I/II clinical trials supported by the National Cancer Institute. Spectros is a venture-supported private concern and markets its products in the U.S. and internationally. For further information, contact Elizabeth van Thillo, Marketing, Spectros Corporation, at info@spectros.com or 650/529.2865

SOURCE Spectros


'/>"/>
SOURCE Spectros
Copyright©2009 PR Newswire.
All rights reserved

Related biology news :

1. Spectros Signs New International Distribution Deals
2. Study identifies warning signs of pregnancy danger
3. Titanium Group Signs Letter of Intent to Acquire Multimilion Dollar Medical Software Company and Its Existing Sales Network
4. Titanium Group Signs Letter of Intent to Acquire Multimilion Dollar Medical Software Company and Its Existing Sales Network
5. Great Ape Trust signs agreement with Universitas Nasional in Jakarta
6. Umbilical cord blood cell therapy may reduce signs and symptoms of Alzheimers disease
7. bioMETRX, Inc. Signs Deal To Acquire Controlling Interest in Biometric Solutions, LLC
8. Unifying the animate and the inanimate designs of nature
9. University of Miami engineer designs stretchable electronics with a twist
10. Engineering technology pinpoints earliest signs of animal life
11. La Jolla Institute signs exclusive license agreement with Medimmune on major asthma discovery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/4/2017)...  GCE Solutions, a global clinical research organization (CRO), announces the ... on October 4, 2017. Shadow is designed to assist medical writers ... 0070 of the European Medicines Agency (EMA) in meeting the requirements ... ... ...
(Date:6/30/2017)... 30, 2017 Today, American Trucking Associations ... of face and eye tracking software, became the ... program. "Artificial intelligence and advanced ... monitor a driver,s attentiveness levels while on the ... to detect fatigue and prevent potential accidents, which ...
(Date:5/16/2017)... TEANECK, N.J. , May 16, 2017  Veratad ... leading provider of online age and identity verification solutions, ... the K(NO)W Identity Conference 2017, May 15 thru May ... Ronald Regan Building and International Trade Center. ... across the globe and in today,s quickly evolving digital ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... ... , ... ComplianceOnline’s Medical Device Summit is back for its 4th year. The ... Francisco, CA. The Summit brings together current and former FDA office bearers, regulators, industry ... officials from around the world to address key issues in device compliance, quality and ...
(Date:10/11/2017)... ... October 11, 2017 , ... Disappearing forests and increased emissions are ... 5.5 million people each year. Especially those living in larger cities are affected by ... in one of the most pollution-affected countries globally - decided to take action. , ...
(Date:10/10/2017)... Los Angeles, CA (PRWEB) , ... ... ... Pharmaceuticals, Inc., a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) ... all uses of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed ...
(Date:10/10/2017)... , Oct. 10, 2017 SomaGenics announced ... the NIH to develop RealSeq®-SC (Single Cell), expected to ... profiling small RNAs (including microRNAs) from single cells using ... highlights the need to accelerate development of approaches to ... "New techniques for measuring levels of ...
Breaking Biology Technology: